Navigating 5 Analyst Ratings For Arcus Biosciences
Portfolio Pulse from Benzinga Insights
Arcus Biosciences (NYSE:RCUS) received mixed analyst ratings with 2 bullish and 3 somewhat bullish out of 5 total. The average 12-month price target was adjusted to $37.6, down 13.56% from previous estimates. Analysts from Truist Securities and Wedbush maintained their ratings, while Mizuho lowered its price target. The company, a clinical-stage biopharmaceutical firm focusing on cancer immunotherapies, showed a revenue decline of -8.82% and a net margin of -261.29%, indicating financial challenges.
March 25, 2024 | 4:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arcus Biosciences received mixed analyst ratings, with a downward revision in the average price target to $37.6, indicating potential short-term pressure on the stock price.
The mixed analyst ratings, combined with a significant decrease in the average price target, suggest a cautious outlook from analysts. This, coupled with the company's reported financial challenges such as a revenue decline and a high net margin, could lead to short-term pressure on RCUS's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100